Aglaroxin C Derivatives Block HCV Entry via Prohibitin Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current direct-acting antiviral (DAA) regimens for Hepatitis C virus (HCV) are facing challenges with drug resistance and affordability issues, particularly in resource-limited countries, and there is a need for new host-targeting compounds that effectively inhibit HCV entry into cells.

Innovation Solution

Development of therapeutic agents targeting the prohibitin-CRaf pathway, specifically using rocaglamide A and aglaroxin C derivatives, which inhibit HCV, dengue virus, and chikungunya virus entries by modulating the prohibitin proteins and their interaction with the CRaf pathway.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If direct-acting antiviral (DAA) regimens are used to treat HCV, then viral inhibition is achieved, but drug resistance develops and efficacy erodes

Engineering Contradiction:

ImproveHCV treatment efficacyVSAvoiddrug resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention targets a different stage of the HCV life cycle by blocking viral entry through host cell receptors (CD81, SR-BI, CLDN1, OCLN, EGFR, NPC1L1) rather than targeting viral replication enzymes. This segmentation of the therapeutic approach at an earlier stage prevents resistance development while maintaining efficacy.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces new lead compounds that act as intermediaries to block the interaction between HCV envelope glycoproteins (E1/E2) and host cell receptors. These compounds mediate the inhibition of viral entry without directly confronting the viral replication machinery, thereby preventing resistance while maintaining treatment efficacy.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If DAA regimens are continuously used, then HCV infection is suppressed, but affordability becomes problematic for patients in resource-limited countries

Engineering Contradiction:

ImproveHCV infection controlVSAvoiddrug affordability

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The invention identifies novel lead compounds with simplified chemical structures compared to existing DAAs, which can be synthesized more cost-effectively. By targeting host cell entry mechanisms rather than complex viral enzymes, the approach enables development of more affordable treatments suitable for resource-limited settings while maintaining infection control efficacy.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Reliability

If HCV entry inhibitors targeting multiple cellular membrane proteins are developed, then viral entry is blocked, but the complexity of the therapeutic target increases

Engineering Contradiction:

Improveviral entry inhibitionVSAvoidtarget complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent develops compounds that can potentially block multiple entry pathways simultaneously by targeting conserved regions of host cell receptors (CD81, SR-BI, CLDN1, OCLN, EGFR, NPC1L1) used by HCV. This multi-functionality approach simplifies the therapeutic strategy by using a single agent to inhibit viral entry through multiple mechanisms, reducing overall treatment complexity while maintaining robust viral entry blockade.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS10085988B1Aglaroxin C and derivatives as HCV entry inhibitors

Publication Date: 2018.10.02 TRUSTEES OF BOSTON UNIV

AI summary

A rocaglamide or a rocaglate derivative, particularly aglaroxin C, blocks hepatitis C virus (HCV) entry with improved potency and therapeutic index.